 CAMBRIDGE, Mass.--BUSINESS WIRE--Infinity Pharmaceuticals, Inc. NASDAQ: INFI Infinity or the Company today presented data from MARIO-275 MAcrophage Reprogramming in Immune Oncology, a randomized, placebo-controlled Phase 2 study evaluating the efficacy and safety of eganelisib in combination with nivolumab Opdivo in platinum-refractory, IO naïve patients with advanced urothelial cancer UC during the 2021 ASCO Genitourinary Cancers Symposium ASCO GU. The objective of MARIO-27 